Core Insights - Public funds' performance rankings for the first half of the year are about to be released, with pharmaceutical funds standing out due to significant excess returns [1] - As of June 18, pharmaceutical funds achieved an average net value growth rate exceeding 19%, capturing nearly half of the top 100 fund performance rankings for the year [1] - This has sparked widespread market interest in the pharmaceutical sector, particularly in the innovative drug field [1]